Sorry to hear that newB
CS mentioned this (via fnarena):
This winding back of trade discounts really doesn't sound sustainable to me, if competition is already tough for pharmacies. Just weakens their pharmacies more in comparison to competition does it not? Maybe I am misunderstanding something? It sort of makes the FY19 guidance seem bit weaker again if this is part of the game plan. Interesting comment I thought.
Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 1
- COMMENTARYFY18 results were in line with expectations. Credit Suisse expects PBS revenues to remain under pressure as some manufacturers are choosing to by-pass wholesale distributors and go directly to pharmacies.Higher growth of non-PBS revenue and the potential winding back of the remaining trade discounts to pharmacy should raise gross profits through FY19.Credit Suisse retains a Neutral rating and reduces the target to $0.82 from $0.84.
2 Morgan Stanley 23/03/2018 5 Underweight $0.80 -1.23%
Sorry about the formatting above
Sorry to hear that newB CS mentioned this (via fnarena): Column...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SIG (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.43 |
Change
0.485(24.9%) |
Mkt cap ! $2.300B | |||
| Open | High | Low | Value | Volume |
| $2.52 | $2.70 | $2.32 | $138.1M | 55.83M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 123400 | $2.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.44 | 1365 | 1 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| SIG (ASX) Chart |
